Abstract
Adherence to medications is poor and suboptimal in many chronic diseases. Nonadherence can reduce treatment effectiveness and can have an impact on healthcare costs. As a consequence, it may alter the cost-effectiveness of drug therapies. This article emphasizes the importance of integrating medication compliance and persistence into pharmacoeconomic evaluations, using osteoporosis as an example. A limited number of studies carried out to date have suggested important economic implications of poor adherence to osteoporosis medications. Therefore, compliance and persistence should be an integral part of clinical studies and pharmacoeconomic analyses in order to estimate the cost-effectiveness of drug therapies in current community practice. Measuring adherence and incorporating it into health economic modeling may, however, pose particular challenges. © 2012 Expert Reviews Ltd.
Author supplied keywords
Cite
CITATION STYLE
Hiligsmann, M., Boonen, A., Rabenda, V., & Reginster, J. Y. (2012, April). The importance of integrating medication adherence into pharmacoeconomic analyses: The example of osteoporosis. Expert Review of Pharmacoeconomics and Outcomes Research. https://doi.org/10.1586/erp.12.8
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.